Key facts
- Predicta Biosciences’s last known valuation is $49.0M (Oct 2025).
- It has raised $29.2M; the latest was Early Stage VC ($24.0M) in Oct 2025.
- Notable investors include Impact Assets, The Engine, Engine Ventures, Illumina Ventures, BrightEdge — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Predicta Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Predicta Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Predicta Biosciences
Developer of an oncology technology platform designed for cancer diagnosis and treatment. The company's platform specializes in integrating multi-omics and liquid biopsy technologies with non-invasive diagnostics, focusing on multiple myeloma to determine the likelihood of a patient responding to immunotherapies, enabling healthcare firms to offer non-invasive blood-based diagnostics that replace bone marrow biopsies and guide optimal immunotherapy decisions.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2023
- Employees
- 11
- Website
- predictabiosciences.com/
- Ownership
- Privately Held (backing)
Predicta Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Predicta Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Predicta Biosciences in its N-PORT filings yet. We sweep new filings monthly.